MTD 214
Alternative Names: MTD-214Latest Information Update: 16 May 2023
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Transplant rejection
Highest Development Phases
- Research Transplant rejection
Most Recent Events
- 14 Sep 2020 MTD 214 is available for licensing as of 14 Sep 2020. http://www.midatechpharma.com/
- 30 Jun 2020 Midatech has patent protection for Q-Sphera™ microsphere technology before June 2020
- 30 Jun 2020 Early research in Transplant rejection in United Kingdom (Parenteral,Controlled release) before June 2020